ODT’s Most-Read Stories This Week—July 15

New products and new offices were the major traffic drivers on ODT’s website this past week. 

The latest product tidings came from Stryker Corp., Motive Health, restor3d, and Bone Biologics. Stryker led pageviews with the launch of its Q Guidance System with Cranial Guidance Software. The software powered by Q provides image-based planning and intraoperative guidance to assist with positioning instruments and identifying patient anatomy during cranial surgery. 

Motive Health enticed cybervisitors to the site with its launch of Motive Knee, an FDA-cleared muscle stimulation device for knee pain, while restor3d followed suit with its first all-metal patient specific instrument (PSI) in ankle arthroplasty. GlobalData speculates the PSI could very likely bolster growth of the ankle replacement market, estimated to be worth $309.1 million last year. 

Bone Biologics Corporation gained a following, too, with news of the first site approval for its NB1 bone graft trial. The multicenter pilot study will evaluate the safety and effectiveness of NB1 in adults who undergo transforaminal lumbar interbody fusion to treat degenerative disc disease.

Osteotec impacted traffic as well with a brief report about its new offices opening in both Ireland and Sweden.

1. Stryker Rolls Out Q Guidance System With Cranial Guidance Software

2. Motive Health Launches Muscle Stimulation Device for Knee Pain

3. restor3d’s All-Metal PSI to Boost Growth in Ankle Replacement Market

4. Bone Biologics Gains Approval to Begin NB1 Bone Graft Trial

5. Osteotec Opens New Offices in Ireland & Sweden